From: Second-generation antipsychotic medications and metabolic disturbance in children and adolescents
Variables | SGA (n = 72) | CTL (n = 79) | Test | P |
---|---|---|---|---|
Age, years, x̃ (range) | 10 (8–12) | 8.70 (6.9–10.8) | U = 2332 | 0.056 |
Gender |  |  | X2 = 0.024 | 0.877 |
 Male, n (%)  Female, n (%) | 41 (56.94) 31(43.06) | 44 (55.70) 35(44.30) | ||
Parents education |  |  | X2 = 1.63 | 0.20 |
 Educated, n (%)  Not educated, n (%) | 43 (59.72) 29 (40.28) | 39 (49.37) 40 (50.63) | ||
Demographic, n (%) |  |  | X2 = 0.16 | 0.69 |
 Urban  Rural | 47 (65.28) 25 (34.72) | 54 (68.35) 25 (31.65) | ||
Psychiatric disorders | Â | Â | Â | Â |
 ASD, n (%)  ADHD, n (%)  ODD/CD, n (%)  Schizophreniform, n (%) | 20 (27.77) 25 (34.72) 4 (5.56) 4 (5.56) | 31 (39.24) 23 (29.11) 5 (6.33) 2 (1.27) | 1.88 0.55 1 0.43 | 0.23 0.46  > 0.99 0.68 |
Comorbidity | Â | Â | Â | Â |
 ASD-depression, n (%)  ASD-low IQ, n (%)  ADHD-low IQ, n (%)  ADHD-anxiety, n (%)  CD-substance abuse, n (%) | 13 (18.06) 3 (4.17) 5 (6.94) 29 (40.28) 3 (4.17) | 9 (11.39) 4 (5.06) 6 (7.59) 27 (34.18) 2 (2.53) | 1.34 1 0.89 0.6 0.67 | 0.25  > 0.99  > 0.99 0.44 0.67 |
 Disease duration, years, x̃ (range) | 1.7 (1.3–3.8) | 2.1 (1.2–3.1) | U = 2568 | 0.303 |
 Disease duration, n (%) |  |  |  |  |
 < 3 years  > 3 years | 56 (77.78) 16 (22.22) | 63 (79.75) 16 (20.25) | X2 = 0.09 | 0.77 |